Journal articles: 'Pranlukast'

1

&NA;. "Pranlukast." Reactions Weekly &NA;, no. 695 (April 1998): 11. http://dx.doi.org/10.2165/00128415-199806950-00038.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

&NA;. "Pranlukast." Reactions Weekly &NA;, no. 743 (March 1999): 11–12. http://dx.doi.org/10.2165/00128415-199907430-00034.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

&NA;. "Pranlukast." Reactions Weekly &NA;, no. 747 (April 1999): 10. http://dx.doi.org/10.2165/00128415-199907470-00030.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

&NA;. "Pranlukast." Reactions Weekly &NA;, no. 1138 (February 2007): 23. http://dx.doi.org/10.2165/00128415-200711380-00068.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Keam, Susan J., Katherine A. Lyseng-Williamson, and Karen L. Goa. "Pranlukast." Drugs 63, no. 10 (2003): 991–1019. http://dx.doi.org/10.2165/00003495-200363100-00005.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

&NA;. "Pranlukast." Reactions Weekly &NA;, no. 865 (August 2001): 11. http://dx.doi.org/10.2165/00128415-200108650-00032.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

&NA;. "Pranlukast." Reactions Weekly &NA;, no. 876 (November 2001): 10. http://dx.doi.org/10.2165/00128415-200108760-00032.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

&NA;. "Pranlukast." Reactions Weekly &NA;, no. 987 (February 2004): 13. http://dx.doi.org/10.2165/00128415-200409870-00039.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Kubota, Jun, Sho Takahashi, Takayuki Suzuki, Akira Ito, Naoe Akiyama, and Noriko Takahata. "Pranlukast treatment and the use of respiratory support in infants with respiratory syncytial virus infection." PLOS ONE 17, no. 5 (May 27, 2022): e0269043. http://dx.doi.org/10.1371/journal.pone.0269043.

Full text

Abstract:

Background In infants, respiratory syncytial virus (RSV) infection occasionally causes severe symptoms requiring respiratory support; however, supportive care is the primary treatment. This study compared the use of respiratory support among infants with RSV infection treated with or without pranlukast. Methods This retrospective cohort study included infants aged <10 months with RSV infection who were admitted to three secondary level hospitals in Japan between 2012 and 2019. The infants were divided into two groups depending on whether they were treated with pranlukast. The primary outcome was the receiving respiratory support (high-flow nasal cannula, nasal continuous positive airway pressure, or ventilator). The secondary outcomes were the length of hospital stay, and the Global Respiratory Severity Score (GRSS) on starting respiratory support or at the time of the worst signs during hospitalization. We performed a propensity score-matched analysis. Results A total of 492 infants, including 147 propensity score-matched pairs, were included in the analysis. The use of respiratory support was significantly lower in infants treated with pranlukast (3.4% [5/147]) than those treated without pranlukast (11.6% [17/147]; P = 0.01). In the propensity score-matched analysis, pranlukast use was associated with a significantly lower chance of needing respiratory support (odds ratio: 0.27, 95% confidence interval: 0.08–0.79; P = 0.01); however, the length of hospital stay (median: 4 days) and the GRSS (median: 2.804 and 2.869 for infants treated with and without pranlukast, respectively) did not differ significantly between propensity score-matched pairs. Conclusions Pranlukast use was associated with a reduced likelihood of requiring respiratory support in infants aged <10 months with RSV infection.

APA, Harvard, Vancouver, ISO, and other styles

10

Figueroa, Eric E., Meghan Kramer, Kevin Strange, and Jerod S. Denton. "CysLT1 receptor antagonists pranlukast and zafirlukast inhibit LRRC8-mediated volume regulated anion channels independently of the receptor." American Journal of Physiology-Cell Physiology 317, no. 4 (October 1, 2019): C857—C866. http://dx.doi.org/10.1152/ajpcell.00281.2019.

Full text

Abstract:

Volume-regulated anion channels (VRACs) encoded by the leucine-rich repeat containing 8 ( LRRC8) gene family play critical roles in myriad cellular processes and might represent druggable targets. The dearth of pharmacological compounds available for studying VRAC physiology led us to perform a high-throughput screen of 1,184 of US Food and Drug Administration-approved drugs for novel VRAC modulators. We discovered the cysteinyl leukotriene receptor 1 (CysLT1R) antagonist, pranlukast, as a novel inhibitor of endogenous VRAC expressed in human embryonic kidney 293 (HEK293) cells. Pranlukast inhibits VRAC voltage-independently, reversibly, and dose-dependently with a maximal efficacy of only ~50%. The CysLT1R pathway has been implicated in activation of VRAC in other cell types, prompting us to test whether pranlukast requires the CysLT1R for inhibition of VRAC. Quantitative PCR analysis demonstrated that CYSLTR1 mRNA is virtually undetectable in HEK293 cells. Furthermore, the CysLT1R agonist leukotriene D4 had no effect on VRAC activity and failed to stimulate Gq-coupled receptor signaling. Heterologous expression of the CysLT1R reconstituted LTD4-CysLT1R- Gq-calcium signaling in HEK293 cells but had no effect on VRAC inhibition by pranlukast. Finally, we show the CysLT1R antagonist zafirlukast inhibits VRAC with an IC50 of ~17 µM and does so with full efficacy. Our data suggest that both pranlukast and zafirlukast are likely direct channel inhibitors that work independently of the CysLT1R. This study provides clarifying insights into the putative role of leukotriene signaling in modulation of VRAC and identifies two new chemical scaffolds that can be used for development of more potent and specific VRAC inhibitors.

APA, Harvard, Vancouver, ISO, and other styles

11

Kim, Seo W., Hunam Kim, Yon J. Ryu, Jin H. Lee, Sung S. Shim, Yoo K. Kim, and Jung H. Chang. "Efficacy and Safety of Modified Pranlukast (Prakanon®) Compared with Pranlukast (Onon®): A Randomized, Open-Label, Crossover Study." Open Respiratory Medicine Journal 10, no. 1 (June 30, 2016): 36–45. http://dx.doi.org/10.2174/1874306401610010036.

Full text

Abstract:

Introduction: Pranlukast is a leukotriene receptor antagonist (LTRA) that is used as an additional controller of mild to moderate asthma. This study compared the efficacy and side effects of two bioequivalent preparations of pranlukast: original pranlukast (Onon®; Ono Pharmaceutical, Japan) and a modified formulation of pranlukast (Prakanon®; Yuhan Co, Korea) in patients with mild to moderate asthma. Methods: Of the 34 subjects screened, 30 patients who were using standard medication to control asthma and scored less than 20 points on the Asthma Control Test™ (ACT) were assigned randomly to one of the two groups in a prospective, open label, crossover study: group 1 received Prakanon® (150 mg/day) and group 2 received Onon® (450 mg/day) for 8 weeks each; after a 1-week rest period, the groups were switched to the alternative medication for further 8 weeks and monitored for 2 more weeks without study medication. Evaluation parameters included the ACT, quality of life questionnaire adult Korean asthmatics (QLQAKA), pulmonary function tests, peripheral blood tests, vital signs, and adverse events. Results: Thirty patients were enrolled and 21 completed the trial: 10 in group 1 and 11 in group 2. The baseline data of the two groups did not differ. No statistical significant differences were observed in efficacy and lung function at each time and in changes from baseline value between the two kinds of pranlukast. The final asthma control rate was 81% with Prakanon® and 76% with Onon®. There were no differences in vital signs and laboratory data at each time and in changes from baseline value between the two drugs. There were no differences in adverse events between the two drugs. The most common side effect was abdominal pain. Drug compliance was high, without differences between the two drugs. Conclusion: These findings suggest that Prakanon® which is an improved formulation of pranlukast at a lower dose than the original formulation, Onon®, has a similar efficacy and side effect profile in the control of persistent asthma.

APA, Harvard, Vancouver, ISO, and other styles

12

&NA;. "Montelukast/pranlukast/zafirlukast." Reactions Weekly &NA;, no. 967 (September 2003): 12. http://dx.doi.org/10.2165/00128415-200309670-00040.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Yelamanchi, Soujanya D., Sumaithangi Thattai Arun Kumar, Archita Mishra, Thottethodi Subrahmanya Keshava Prasad, and Avadhesha Surolia. "Metabolite Dysregulation by Pranlukast in Mycobacterium tuberculosis." Molecules 27, no. 5 (February 24, 2022): 1520. http://dx.doi.org/10.3390/molecules27051520.

Full text

Abstract:

Mycobacterium tuberculosis has been infecting millions of people worldwide over the years, causing tuberculosis. Drugs targeting distinct cellular mechanisms including synthesis of the cell wall, lipids, proteins, and nucleic acids in Mtb are currently being used for the treatment of TB. Although extensive research is being carried out at the molecular level in the infected host and pathogen, the identification of suitable drug targets and drugs remains under explored. Pranlukast, an allosteric inhibitor of MtArgJ (Mtb ornithine acetyltransferase) has previously been shown to inhibit the survival and virulence of Mtb. The main objective of this study was to identify the altered metabolic pathways and biological processes associated with the differentially expressed metabolites by PRK in Mtb. Here in this study, metabolomics was carried out using an LC-MS/MS-based approach. Collectively, 50 metabolites were identified to be differentially expressed with a significant p-value through a global metabolomic approach using a high-resolution mass spectrometer. Metabolites downstream of argJ were downregulated in the arginine biosynthetic pathway following pranlukast treatment. Predicted human protein interactors of pranlukast-treated Mtb metabolome were identified in association with autophagy, inflammation, DNA repair, and other immune-related processes. Further metabolites including N-acetylglutamate, argininosuccinate, L-arginine, succinate, ergothioneine, and L-phenylalanine were validated by multiple reaction monitoring, a targeted mass spectrometry-based metabolomic approach. This study facilitates the understanding of pranlukast-mediated metabolic changes in Mtb and holds the potential to identify novel therapeutic approaches using metabolic pathways in Mtb.

APA, Harvard, Vancouver, ISO, and other styles

14

Yonetomi, Y., M. Fujita, N. Nakagawa, and T. Obata. "Preclinical pharmacology of pranlukast." Clinical & Experimental Allergy Reviews 1, no. 3 (November 2001): 210–17. http://dx.doi.org/10.1046/j.1472-9725.2001.t01-1-00008.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

&NA;. "Pranlukast protects against deteriorating asthma control." Inpharma Weekly &NA;, no. 1086 (May 1997): 16. http://dx.doi.org/10.2165/00128413-199710860-00031.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Iikura, Y., K. Miura, Y. Odajima, T. Imai, H. Sugimoto, and M. Ebisawa. "Efficacy of pranlukast in childhood asthma." Clinical & Experimental Allergy Reviews 1, no. 3 (November 2001): 287–96. http://dx.doi.org/10.1046/j.1472-9725.2001.t01-1-00014.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

&NA;. "Pranlukast demonstrates long-term efficacy in asthma." Inpharma Weekly &NA;, no. 1303 (September 2001): 6. http://dx.doi.org/10.2165/00128413-200113030-00015.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Kim, Sujeong, and Jong-Myung Lee. "A Case of Pranlukast-Induced Anaphylactic Shock." Allergy, Asthma & Immunology Research 8, no. 3 (2016): 276. http://dx.doi.org/10.4168/aair.2016.8.3.276.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Yang, X. X., W. S. Powell, L. J. Xu, and J. G. Martin. "Strain dependence of the airway response to dry-gas hyperpnea challenge in the rat." Journal of Applied Physiology 86, no. 1 (January 1, 1999): 152–58. http://dx.doi.org/10.1152/jappl.1999.86.1.152.

Full text

Abstract:

The aim of the study was to investigate strain dependence and mechanisms of airway responses to dry-gas hyperpnea challenge in the rat. We studied responses in a strain that is hyperresponsive to methacholine, Fischer 344 (F-344); in two normoresponsive strains, Lewis and ACI; and in an atopic but normoresponsive strain, Brown Norway (BN). We examined the effects of a neurokinin (NK) 1-receptor (CP-99994), an NK2-receptor (SR-48968), and a leukotriene D4(LTD4)-receptor antagonist (pranlukast) on responses to hyperpnea challenge in BN rats. The animals were ventilated with a tidal volume of 8 ml/kg and a frequency of 150 breaths/min with either a dry or humidified mixture of 5% CO2-95% O2 for 5 min for hyperpnea challenge, whereas responses to challenge were measured during spontaneous breathing. Pulmonary resistance increased after dry-gas challenge in BN and ACI but not in F-344 and Lewis rats. CP-99994, SR-48968, and pranlukast significantly attenuated the increase in pulmonary resistance after dry-gas challenge. There were no significant differences in responsiveness to airway challenge with LTD4 among the BN, F-344 and ACI rats. We conclude that responses to dry-gas hyperpnea challenge are strain dependent in rats and are mediated by NKs and LTD4.

APA, Harvard, Vancouver, ISO, and other styles

20

Tsuji, Yuichirou, Kenji Narui, Takaaki Takayanagi, Hiroshi Chikaoka, Seiji Takita, Youji Iikura, and Tadasu Sakai. "Effectiveness of pranlukast hydrate for Henoch-Schoenlein purpura." Nihon Shoni Jinzobyo Gakkai Zasshi 11, no. 2 (1998): 185–90. http://dx.doi.org/10.3165/jjpn.11.185.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Theron, A. J., H. C. Steel, G. R. Tintinger, C. M. Gravett, R. Anderson, and C. Feldman. "Cysteinyl Leukotriene Receptor-1 Antagonists as Modulators of Innate Immune Cell Function." Journal of Immunology Research 2014 (2014): 1–16. http://dx.doi.org/10.1155/2014/608930.

Full text

Abstract:

Cysteinyl leukotrienes (cysLTs) are produced predominantly by cells of the innate immune system, especially basophils, eosinophils, mast cells, and monocytes/macrophages. Notwithstanding potent bronchoconstrictor activity, cysLTs are also proinflammatory consequent to their autocrine and paracrine interactions with G-protein-coupled receptors expressed not only on the aforementioned cell types, but also on Th2 lymphocytes, as well as structural cells, and to a lesser extent neutrophils and CD8+cells. Recognition of the involvement of cysLTs in the immunopathogenesis of various types of acute and chronic inflammatory disorders, especially bronchial asthma, prompted the development of selective cysLT receptor-1 (cysLTR1) antagonists, specifically montelukast, pranlukast, and zafirlukast. More recently these agents have also been reported to possess secondary anti-inflammatory activities, distinct from cysLTR1 antagonism, which appear to be particularly effective in targeting neutrophils and monocytes/macrophages. Underlying mechanisms include interference with cyclic nucleotide phosphodiesterases, 5′-lipoxygenase, and the proinflammatory transcription factor, nuclear factor kappa B. These and other secondary anti-inflammatory mechanisms of the commonly used cysLTR1 antagonists are the major focus of the current review, which also includes a comparison of the anti-inflammatory effects of montelukast, pranlukast, and zafirlukast on human neutrophilsin vitro, as well as an overview of both the current clinical applications of these agents and potential future applications based on preclinical and early clinical studies.

APA, Harvard, Vancouver, ISO, and other styles

22

&NA;. "Pranlukast was found to be 'safe and well tolerated'." Reactions Weekly &NA;, no. 667 (September 1997): 4. http://dx.doi.org/10.2165/00128415-199706670-00009.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Matsuse, Hiroto, and Shigeru Kohno. "Leukotriene receptor antagonists pranlukast and montelukast for treating asthma." Expert Opinion on Pharmacotherapy 15, no. 3 (December 19, 2013): 353–63. http://dx.doi.org/10.1517/14656566.2014.872241.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Schurman, Scott J., Janice M. Alderman, Marc Massanari, Atilano G. Lacson, and Sharon A. Perlman. "Tubulointerstitial Nephritis Induced by the Leukotriene Receptor Antagonist Pranlukast." Chest 114, no. 4 (October 1998): 1220–23. http://dx.doi.org/10.1378/chest.114.4.1220.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Kobayashi, Shigeto, Shyugo Ishizuka, Naoto Tamura, Makiyo Takaya, Kazuhiko Kaneda, and Hiroshi Hashimoto. "Churg?Strauss syndrome (CSS) in a patient receiving pranlukast." Clinical Rheumatology 22, no. 6 (December 1, 2003): 491–92. http://dx.doi.org/10.1007/s10067-003-0791-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Shimbo, Junsuke, Osamu Onodera, Keiko Tanaka, and Shoji Tsuji. "Churg-Strauss syndrome and the leukotriene receptor antagonist pranlukast." Clinical Rheumatology 24, no. 6 (December 2, 2004): 661–62. http://dx.doi.org/10.1007/s10067-004-1035-z.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Schierle, Simone, Jurema Schmidt, Astrid Kaiser, and Daniel Merk. "Selective Optimization of Pranlukast to Farnesoid X Receptor Modulators." ChemMedChem 13, no. 23 (November 20, 2018): 2530–45. http://dx.doi.org/10.1002/cmdc.201800549.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Hao, Yanli, Lan Wang, Jun Li, Nan Liu, Jinfeng Feng, Mojiao Zhao, and Xiaoning Zhang. "Enhancement of Solubility, Transport Across Madin-Darby Canine Kidney Monolayers and Oral Absorption of Pranlukast Through Preparation of a Pranlukast-Phospholipid Complex." Journal of Biomedical Nanotechnology 11, no. 3 (March 1, 2015): 469–77. http://dx.doi.org/10.1166/jbn.2015.1914.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Yoshida, Ishizaki, Shoji, Onuma, Nakagawa, Nakabayashi, Akahori, Hasegawa, and Amayasu. "Effect of pranlukast on bronchial inflammation in patients with asthma." Clinical & Experimental Allergy 30, no. 7 (July 2000): 1008–14. http://dx.doi.org/10.1046/j.1365-2222.2000.00834.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

SAKAGUCHI, KAZUO, JUNKO KUWABARA, AKIYO SAITOU, EMIKO MIYASHITA, YOSHIAKI TAKAYAMA, MASAHIRO AIZAKI, HISAO KUMAKURA, SHOICHI TANGE, and SHUICHI ICHIKAWA. "The Pharmacokinetic Interaction between Theophylline and Leukotriene Receptor Antagonist, Pranlukast." Japanese Journal of Hospital Pharmacy 23, no. 6 (1997): 507–11. http://dx.doi.org/10.5649/jjphcs1975.23.507.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Watanabe, Toru, Yasufumi Iinuma, Shin-ichi Naito, and Koju Nitta. "Eosinophilic tumor in a patient with bronchial asthma receiving pranlukast." European Journal of Pediatrics 166, no. 2 (August 17, 2006): 183–84. http://dx.doi.org/10.1007/s00431-006-0226-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Nakade, Susumu, Akinori Yamauchi, Junji Komaba, Tomoya Ohno, Junsaku Kitagawa, Naoki Honda, Chihiro Hasegawa, et al. "Effect of Clarithromycin on the Pharmacokinetics of Pranlukast in Healthy Volunteers." Drug Metabolism and Pharmacokinetics 23, no. 6 (2008): 428–33. http://dx.doi.org/10.2133/dmpk.23.428.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Yoshifuku, Kousuke, Shoji Matsune, and Yuichi Kurono. "The Efficacy of Pranlukast Hydrate for Chronic Sinusitis with Nasal Polyp." Practica Oto-Rhino-Laryngologica 101, no. 9 (2008): 715–20. http://dx.doi.org/10.5631/jibirin.101.715.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Kim, Hyeong-Eun, Jun-Seok Hwang, Sun-Hang Cho, Young-Jin Kim, and Kang-Moo Huh. "Preparation and Characterization of Poly(ethylene glycol) Based Pranlukast Solid Dispersion." Polymer Korea 36, no. 1 (January 25, 2012): 41–46. http://dx.doi.org/10.7317/pk.2012.36.1.041.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

UNDERWOOD, D., S. BOCHNOWICZ, R. OSBORN, S. NEWSHOLME, T. TORPHY, and D. HAY. "426 The cysteinyl-leukotriene (CysLT) receptor antagonist, pranlukast, attenuates airway inflammation." Journal of Allergy and Clinical Immunology 97, no. 1 (January 1996): 289. http://dx.doi.org/10.1016/s0091-6749(96)80644-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Brocks, D. R., J. W. Upward, P. Georgiou, G. Stelman, E. Doyle, E. Allen, P. Wyld, and M. J. Dennis. "The single and multiple dose pharmacokinetics of pranlukast in healthy volunteers." European Journal of Clinical Pharmacology 51, no. 3-4 (December 12, 1996): 303–8. http://dx.doi.org/10.1007/s002280050202.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Kanazawa, Hiroshi. "Effects of Pranlukast on Vascular Endothelial Growth Factor Levels in Asthma." Chest 127, no. 4 (April 2005): 1461. http://dx.doi.org/10.1016/s0012-3692(15)34509-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Sun, Tao, Zhihua Wu, Mengyao Luo, Donghai Lin, and Chenyun Guo. "Pranlukast, a novel binding ligand of human Raf1 kinase inhibitory protein." Biotechnology Letters 38, no. 8 (May 5, 2016): 1375–80. http://dx.doi.org/10.1007/s10529-016-2117-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Kanazawa, Hiroshi. "Effects of Pranlukast on Vascular Endothelial Growth Factor Levels in Asthma." CHEST Journal 127, no. 4 (April 1, 2005): 1461. http://dx.doi.org/10.1378/chest.127.4.1461.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Baek, In-hwan, Jung-Soo Kim, Eun-Sol Ha, Gwang-Ho Choo, Wonkyung Cho, Sung-Joo Hwang, and Min-Soo Kim. "Dissolution and oral absorption of pranlukast nanosuspensions stabilized by hydroxypropylmethyl cellulose." International Journal of Biological Macromolecules 67 (June 2014): 53–57. http://dx.doi.org/10.1016/j.ijbiomac.2014.03.006.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Takahashi, Yukitoshi, Katsumi Imai, Hitoshi Ikeda, Yuko Kubota, Etsuko Yamazaki, and Fuminobu Susa. "Open study of pranlukast add-on therapy in intractable partial epilepsy." Brain and Development 35, no. 3 (March 2013): 236–44. http://dx.doi.org/10.1016/j.braindev.2012.04.001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

TAKAHASHI, Naotsugu, Tomoaki IWANAGA, Hisamichi AIZAWA, Hiroshi KOTO, Kentaroh WATANABE, Reiko KISHIKAWA, Togo IKEDA, Shunsuke SHOJI, Sankei NISHIMA, and Nobuyuki KARA. "Acute Interstitial Pneumonia Induced by ONO-1078 (pranlukast), a Leukotriene Receptor Antagonist." Internal Medicine 40, no. 8 (2001): 791–94. http://dx.doi.org/10.2169/internalmedicine.40.791.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Lee, Sin Hyung, Jae Jeong Shim, Kyung Kyu Kim, Hye Cheol Jeong, Young Hwan Kwon, Je Hyeong Kim, Sung Yong Lee, et al. "Effects of pranlukast on ovalbumin induced early-phase bronchoconstriction in guinea pigs." Tuberculosis and Respiratory Diseases 46, no. 5 (1999): 697. http://dx.doi.org/10.4046/trd.1999.46.5.697.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

KOBAYASHI, Maiko, Takako MASUDA, Yusuke KINOSHITA, and Hiroyuki HARA. "Churg-Strauss Syndrome in a Patient Receiving Pranlukast as Treatment for Asthma." Nishi Nihon Hifuka 67, no. 4 (2005): 319–22. http://dx.doi.org/10.2336/nishinihonhifu.67.319.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Endo, Shuichiro, Minoru Gotoh, Kimihiro Okubo, Kazuhiro Hashiguchi, Hidenori Suzuki, and Keisuke Masuyama. "Trial of pranlukast inhibitory effect for cedar exposure using an OHIO chamber." Journal of Drug Assessment 1, no. 1 (February 22, 2012): 48–54. http://dx.doi.org/10.3109/21556660.2012.703630.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Velázquez-Quesada, Inés, Angel J. Ruiz-Moreno, Diana Casique-Aguirre, Charmina Aguirre-Alvarado, Fabiola Cortés-Mendoza, Marisol de la Fuente-Granada, Carlos García-Pérez, et al. "Pranlukast Antagonizes CD49f and Reduces Stemness in Triple-Negative Breast Cancer Cells." Drug Design, Development and Therapy Volume 14 (May 2020): 1799–811. http://dx.doi.org/10.2147/dddt.s247730.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Ichiyama, T., S. Hasegawa, M. Umeda, K. Terai, T. Matsubara, and S. Furukawa. "Pranlukast inhibits NF-κB activation in human monocytes/macrophages and T cells." Clinical & Experimental Allergy 33, no. 6 (June 2003): 802–7. http://dx.doi.org/10.1046/j.1365-2222.2003.01673.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Inoue, Ryosuke, Takahide Teramoto, Susumu Nakade, Hiroyuki Okamoto, Eiji Yukawa, Shun Higuchi, Naomi Kondo, and Haruki Mikawa. "Population pharmacokinetics of pranlukast hydrate dry syrup in children with bronchial asthma." Allergology International 52, no. 4 (2003): 213–18. http://dx.doi.org/10.1046/j.1323-8930.2003.00304.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Horiguchi, Takahiko, Soichi Tachikawa, Rieko Kondo, Junichi Miyazaki, Yasushi Sasaki, Kengo Banno, and Misuzu Handa. "Evaluation of the Combined Effect of Pranlukast during High-dose Steroid Inhalation." Arzneimittelforschung 52, no. 11 (December 26, 2011): 813–16. http://dx.doi.org/10.1055/s-0031-1299972.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Nagata, Makoto, Keiko Saito, Izumi Kikuchi, Koichi Hagiwara, and Minoru Kanazawa. "Effect of the Cysteinyl Leukotriene Antagonist Pranlukast on Transendothelial Migration of Eosinophils." International Archives of Allergy and Immunology 137, no. 1 (2005): 2–6. http://dx.doi.org/10.1159/000085424.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Journal articles on the topic 'Pranlukast'

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles